O-022Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. (20th June 2018) - Lesniewski-Kmak, K; Moiseenko, V; Saunders, M; Wasan, H; Argiles, G; Borg, C; Creemers, G; Fedyanin, M; Glynne-Jones, R; Pfeiffer, P; Punt, C; Stroyakovskiy, D; et al.